Abstract：
BACKGROUND: In Bangladesh, only a fraction of prostate cancer patients are diagnosed annually due to lack of symptom awareness and screening challenges, resulting in high mortality. Aiming to improve screening methods, we evaluated X-ray cross-complementing gene 1 (XRCC1) Arg194Gln and Xeroderma pigmentosum group D (XPD) Lys751Gln polymorphisms to determine their relevance as potential markers for predicting prostate cancer risk, severity and clinical parameters in Bangladeshi population.
RESULTS: This study included 132 prostate cancer patients and 135 healthy controls. Genotype analysis was done from blood samples by the PCR-RFLP method. The XRCC1 Trp/Trp genotype was associated with prostate cancer (ORadj = 5.51; 95% CI = 1.13-26.78; p-value = 0.03) compared to Arg/Arg genotype. No significant association was found between the XPD variants and prostate cancer risk. The XRCC1 Trp/Trp genotype increased prostate cancer risk in smokers and non-smokers but was statistically non-significant. In individuals without a family history of cancer, the XRCC1 Trp/Trp genotype had a non-significant 4.64-fold higher risk (ORadj=4.64; 95% CI = 0.88-24.36; p-value = 0.07), while the XPD Gln/Gln had a 2.66-fold non-significant higher risk (ORadj=2.66; 95% CI = 0.88-8.10; p-value = 0.09). The XRCC1 Trp/Trp variant was associated with hematuria risk, higher mean serum creatinine, and mean prostate-specific antigen (PSA) levels in prostate cancer patients. The XPD Gln/Gln variant was only associated with higher mean serum creatinine levels.
CONCLUSIONS: Our findings suggest that XRCC1 screening may be used as a biomarker for prostate cancer to improve early diagnosis in Bangladesh.
RESULTS: This study included 132 prostate cancer patients and 135 healthy controls. Genotype analysis was done from blood samples by the PCR-RFLP method. The XRCC1 Trp/Trp genotype was associated with prostate cancer (ORadj = 5.51; 95% CI = 1.13-26.78; p-value = 0.03) compared to Arg/Arg genotype. No significant association was found between the XPD variants and prostate cancer risk. The XRCC1 Trp/Trp genotype increased prostate cancer risk in smokers and non-smokers but was statistically non-significant. In individuals without a family history of cancer, the XRCC1 Trp/Trp genotype had a non-significant 4.64-fold higher risk (ORadj=4.64; 95% CI = 0.88-24.36; p-value = 0.07), while the XPD Gln/Gln had a 2.66-fold non-significant higher risk (ORadj=2.66; 95% CI = 0.88-8.10; p-value = 0.09). The XRCC1 Trp/Trp variant was associated with hematuria risk, higher mean serum creatinine, and mean prostate-specific antigen (PSA) levels in prostate cancer patients. The XPD Gln/Gln variant was only associated with higher mean serum creatinine levels.
CONCLUSIONS: Our findings suggest that XRCC1 screening may be used as a biomarker for prostate cancer to improve early diagnosis in Bangladesh.
摘要：
背景：在孟加拉国，由于缺乏症状意识和筛查挑战，每年只有一小部分前列腺癌患者被诊断出来，导致高死亡率。旨在改进筛选方法,我们评估了X线交叉互补基因1（XRCC1）Arg194Gln和着色性干皮病D组（XPD）Lys751Gln多态性，以确定它们作为预测前列腺癌风险的潜在标志物的相关性，孟加拉国人群的严重程度和临床参数。
结果：这项研究包括132名前列腺癌患者和135名健康对照。通过PCR-RFLP方法从血液样品中进行基因型分析。与Arg/Arg基因型相比，XRCC1Trp/Trp基因型与前列腺癌相关（ORadj=5.51；95％CI=1.13-26.78；p值=0.03）。在XPD变体和前列腺癌风险之间没有发现显著关联。XRCC1Trp/Trp基因型增加了吸烟者和非吸烟者的前列腺癌风险，但在统计学上不显着。在没有癌症家族史的个体中，XRCC1Trp/Trp基因型的风险无显著增加4.64倍（ORadj=4.64；95％CI=0.88-24.36；p值=0.07），而XPDGln/Gln的非显著风险较高2.66倍(ORadj=2.66;95%CI=0.88-8.10;p值=0.09).XRCC1Trp/Trp变异与血尿风险相关，较高的平均血清肌酐，和前列腺癌患者的平均前列腺特异性抗原（PSA）水平。XPDGln/Gln变体仅与较高的平均血清肌酐水平相关。
结论：我们的研究结果表明，在孟加拉国，XRCC1筛查可用作前列腺癌的生物标志物，以改善早期诊断。
结果：这项研究包括132名前列腺癌患者和135名健康对照。通过PCR-RFLP方法从血液样品中进行基因型分析。与Arg/Arg基因型相比，XRCC1Trp/Trp基因型与前列腺癌相关（ORadj=5.51；95％CI=1.13-26.78；p值=0.03）。在XPD变体和前列腺癌风险之间没有发现显著关联。XRCC1Trp/Trp基因型增加了吸烟者和非吸烟者的前列腺癌风险，但在统计学上不显着。在没有癌症家族史的个体中，XRCC1Trp/Trp基因型的风险无显著增加4.64倍（ORadj=4.64；95％CI=0.88-24.36；p值=0.07），而XPDGln/Gln的非显著风险较高2.66倍(ORadj=2.66;95%CI=0.88-8.10;p值=0.09).XRCC1Trp/Trp变异与血尿风险相关，较高的平均血清肌酐，和前列腺癌患者的平均前列腺特异性抗原（PSA）水平。XPDGln/Gln变体仅与较高的平均血清肌酐水平相关。
结论：我们的研究结果表明，在孟加拉国，XRCC1筛查可用作前列腺癌的生物标志物，以改善早期诊断。
